Gyre Therapeutics, Inc. Assets Held-for-sale, Current (Deprecated 2014-01-31)
Gyre Therapeutics, Inc. (GYRE) had Assets Held-for-sale, Current (Deprecated 2014-01-31) of $317.00 thousand as of 2013-09-30, per its 10-Q filed 2013-11-06.
Discontinued › Notes
us-gaap:AssetsHeldForSaleCurrent · last filed 2013-11-06
- 2013-09-30: Assets Held-for-sale, Current (Deprecated 2014-01-31) $317.00K.
- 2013-06-30: Assets Held-for-sale, Current (Deprecated 2014-01-31) $417.00K; Assets Held-for-sale, Current (Deprecated 2014-01-31) as first filed $413.00K.
| Period end | Assets Held-for-sale, Current (Deprecated 2014-01-31) | Assets Held-for-sale, Current (Deprecated 2014-01-31) as first filed |
|---|---|---|
| 2013-09-30 | $317.00K 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $417.00K 10-Q · filed 2013-11-06 | $413.00K 10-Q · filed 2013-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |